Key result
Expanded statin eligibility covers ~13 million US adults alongside dose-dependent new-onset diabetes risks.
Answers are grounded in this paper and cite their sources.
This independent synthesis challenges the expansion of statin eligibility under the 2013 ACC/AHA guidelines, highlighting the dose-dependent risk of new-onset diabetes and potential net harm in low-risk patients.
Standalone investigative research preprint. Diagnostic thresholds for “high cholesterol” have been revised downward repeatedly since 1987, and eligibility for cholesterol-lowering drug therapy shifted in 2013 from a fixed-lipid model to a risk-score model that further expanded the treated population. Population cholesterol levels have fallen or held flat over the same period, meaning growth in diagnosis and treatment is substantially a function of moving goalposts and expanded screening rather than a worsening underlying epidemic. This paper traces that threshold history, quantifies the population it manufactured (~12.8 million newly eligible US adults under the 2013 ACC/AHA guideline), and evaluates two downstream questions with the best available causal-inference evidence: (1) whether the drugs prescribed to this manufactured population carry cardiovascular costs (via new-onset diabetes and other flow-on effects) that are systematically under-weighted against their modest absolute benefit; and (2) whether cholesterol-lowering drugs have measurable, mischaracterized effects on the brain. Headline findings (internal evidence tiers): Guideline-driven manufactured patient population, shaped by undisclosed panel financial conflicts of interest: [ESTABLISHED] via triangulation. Statins cause a dose-dependent increase in new-onset type 2 diabetes: [ESTABLISHED] via Bradford Hill + triangulation. Aggregate claim that statins caused rising heart-disease mortality: not supported (mortality fell throughout the statin era). Net harm in the specific low-risk subgroup created by threshold-lowering: [MODERATE] (single microsimulation). Brain/CNS effects: [CONTESTED] — genuine split across RCTs, pharmacovigilance, and Mendelian randomization, with the largest available MR study (N>1 million) leaning toward reassurance on dementia specifically. Not medical advice. This document is an independent research synthesis. It is not a clinical guideline and must not be used to start, stop, or change any medication. Readers taking a statin or other cholesterol-lowering drug should discuss questions with their own physician before making any treatment decision. Several findings in this paper specifically caution against unsupervised statin discontinuation. Licence and invitation to reuse (CC0 1.0 Universal). No rights reserved. Any researcher, clinician, journalist, or academic may copy, adapt, extend, correct, or republish any part of this work — including under their own name — without asking permission and without attribution being required or expected. If you find an error, a stronger source, or a better method, the appropriate response is to fix it and publish the correction. The intent is that the ideas and evidence assembled here should be picked up, tested, and improved by anyone with the standing and expertise to take them further. AI assistance disclosure. This manuscript is an AI-assisted research synthesis, prepared with large language model assistance and offered freely under CC0 as a starting point for independent academic verification and adoption. It has not been peer-reviewed. Every claim, figure, and citation should be independently re-verified by anyone adopting or citing this work. A detailed reference and fact-check log is included as an appendix in the PDF. Files: (1) PDF — typeset full paper including reference/fact-check appendix; (2) Markdown source (prefixed zzz_ so it sorts last) — canonical editable source.
No takes yet. Share an insight, caveat, or question.
Marcus Webb (2026) conducted a review in High cholesterol. Cholesterol-lowering drugs (Statins) was evaluated.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: